Wearable AI to monitor heart function after lymphoma or sarcoma treatment
Official title: WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
Run by Mayo Clinic · NCT07058064 · Data updated 2026-11-12
This project will test whether a smartwatch-based AI ECG combined with periodic echocardiograms can find early heart damage in lymphoma or sarcoma survivors treated with anthracycline chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | July 18, 2025 |
| Main results expected | June 29, 2029 |
| Study ends | June 29, 2029 |
| Registry record updated | October 15, 2025 |
| Trial ID | NCT07058064 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with lymphoma or sarcoma who are starting anthracycline treatment or are within one year after finishing it, have LVEF ≥50%, no prior heart failure or persistent arrhythmias, and can give informed consent and comply with study procedures.
✕Probably not a fit
Patients with baseline LVEF <50%, a prior history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm are excluded and unlikely to benefit from this surveillance strategy.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional program uses an Apple Watch with AI-enabled ECG monitoring alongside standard echocardiograms and LVEF measurements to provide long-term cardiovascular surveillance for cancer survivors. Participants are lymphoma or sarcoma patients who are starting anthracycline therapy or are within one year after completing it, and who do not have preexisting reduced LVEF or disqualifying arrhythmias. The study collects ECG data from a wearable, periodic echocardiographic imaging including LVEF, and biospecimens to correlate findings. The goal is a cost-effective, feasible approach to detect cardiotoxicity earlier and reduce progression to heart failure over extended follow-up.
Why it matters
Potential benefit: If successful, this approach could enable earlier, low-cost detection of cardiotoxicity using wearable monitoring, helping prevent progression to heart failure and reduce related morbidity and mortality.
How similar studies have gone: Prior research has shown AI-enabled ECGs can detect reduced LVEF and that wearable ECG monitoring is feasible, but long-term outcome data specifically in cancer survivors remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ability to understand study procedures and being willing to comply with them for the entire study length * diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy Exclusion Criteria: * LVEF \<50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm * Unwilling or unable to give written informed consent * Participants who have opted out of the Minnesota Research Authorization
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Joerg Herrmann, MD — Mayo Clinic
- Study coordinator: Tera Peck
- Email: Peck.Tera@mayo.edu
- Phone: 507-266-2123
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Helping adolescent and young adult cancer survivors manage symptoms and stay engaged in post-treatment care
This trial will test whether AYA STEPS, a six-session digital program, can help adolescent and young adult cancer survivors reduce symptoms and keep up with recommended follow-up care.
-
Digital peer support for young adults with cancer
This study is testing a digital support program to see if it can help young adults who have finished cancer treatment by connecting them with trained peers for guidance and encouragement.
-
Validation of a blood test for early cancer detection and monitoring
This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.